{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004131","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.390188+00:00","generated_at":"2026-06-20T18:03:09.649706+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024","bullets":["Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.","BEAM-101 (SCD): BEACON trial sentinel cohort enrollment completion and expansion cohort initiation expected in 2023; data from multiple patients in 2024.","BEAM-201 (T-ALL/T-LL): FDA IND clearance; first patient dosing expected by mid-2023 in Phase 1/2 trial.","BEAM-301 (GSDIa) regulatory submission planned by late 2023/early 2024; BEAM-302 (AATD) submission planned early 2024.","North Carolina manufacturing facility expected to initiate GMP operations in late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004131","json":"https://secwatch.observer/filing/0001193125-23-004131.json","markdown":"https://secwatch.observer/filing/0001193125-23-004131.md","text":"https://secwatch.observer/filing/0001193125-23-004131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/0001193125-23-004131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/d393225d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:03:09.649706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}